Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
Open Access
- 9 July 2013
- journal article
- review article
- Published by Hindawi Limited in Stem Cells International
- Vol. 2013, 1-12
- https://doi.org/10.1155/2013/724360
Abstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML.Funding Information
- American University of Beirut
This publication has 83 references indexed in Scilit:
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell, 2012
- Further phenotypic characterization of the primitive lineage− CD34+CD38−CD90+CD45RA− hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemiaBlood Cancer Journal, 2011
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemiaLeukemia, 2010
- Critical molecular pathways in cancer stem cells of chronic myeloid leukemiaLeukemia, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemiaNature Genetics, 2009
- IFNα activates dormant haematopoietic stem cells in vivoNature, 2009
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature, 2009
- PML targeting eradicates quiescent leukaemia-initiating cellsNature, 2008
- Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In VivoCancer Cell, 2007